- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, Placebo (for sarilumab), Methotrexate, Folic Acid
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 45
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1705–1728
of 13,084
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 109
- States / cities
- Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Sevelamer hydrochloride, Calcium-based phosphate binder
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 72
- States / cities
- Gadsden, Alabama • Huntsville, Alabama • Tucson, Arizona + 63 more
- Conditions
- Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
- Interventions
- Robotic NSM, Open NSM
- Device · Procedure
- Lead sponsor
- Intuitive Surgical
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 15
- States / cities
- Irvine, California • Los Angeles, California • Jacksonville, Florida + 12 more
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 27
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 23 more
- Conditions
- Prostate Cancer
- Interventions
- SpaceOAR System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Campbell, California • Sacramento, California + 16 more
- Conditions
- Multi-Drug Resistant Organism Colonization
- Interventions
- Allogeneic Microbiota in Glycerol (9%) (AMG)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Hinsdale, Illinois + 1 more
- Conditions
- Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT)
- Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
- Conditions
- Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 454
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 305 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more
- Conditions
- Cervical Dysplasia
- Interventions
- LuViva Advanced Cervical Scan
- Diagnostic Test
- Lead sponsor
- Guided Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Bay City, Michigan + 1 more
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- Placebo, EP-1300
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 2,621 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 136
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 103 more
- Conditions
- Venous Thrombosis
- Interventions
- Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
- Conditions
- Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
- Interventions
- Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Diego, California • Delray Beach, Florida + 6 more
- Conditions
- Congenital Disorders
- Interventions
- Spironolactone (drug)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hypertension, Retinal Disorder, Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Psoriasis
- Interventions
- Guselkumab, Placebo, Secukinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,048 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oceanside, California + 38 more
- Conditions
- Hepatorenal Syndrome
- Interventions
- Ifetroban Injection, Placebo
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Propranolol, Questionnaire Administration
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Buffalo, New York
- Conditions
- Depressive Disorder, Major
- Interventions
- Rapastinel
- Drug
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 128
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 104 more
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
- Conditions
- Heart Failure
- Interventions
- CRT-D
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 699 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 37 more